Group-Based Contingency Management for Substance Abuse Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

312 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Substance Abuse

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Contingency management Substance abuse treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contingency management

Receive rewards (prizes) abstinence and attendance

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence
* willing to provide breath and urine samples for 12 weeks
* English speaking
* willing to sign informed consent

Exclusion Criteria

* serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)
* dementia (\<23 on the Mini Mental State Exam; Folstein et al. 1975)
* in recovery from pathological gambling

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nancy Petry, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

UConn Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Connecticut Health Center

Farmington, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DA018883

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NIDA-18883-1

Identifier Type: -

Identifier Source: org_study_id

Group-Based Contingency Management for Substance Abuse Treatment - 1